Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Raw Materials (2019 - 2025)

IGC Pharma has reported Raw Materials over the past 7 years, most recently at $446000.0 for Q3 2025.

  • Quarterly Raw Materials fell 59.6% to $446000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $446000.0 through Sep 2025, down 59.6% year-over-year, with the annual reading at $1.1 million for FY2025, 0.45% changed from the prior year.
  • Raw Materials was $446000.0 for Q3 2025 at IGC Pharma, down from $1.1 million in the prior quarter.
  • Over five years, Raw Materials peaked at $3.0 million in Q4 2022 and troughed at $446000.0 in Q3 2025.
  • The 5-year median for Raw Materials is $2.1 million (2023), against an average of $1.8 million.
  • Year-over-year, Raw Materials surged 910.57% in 2021 and then tumbled 59.6% in 2025.
  • A 5-year view of Raw Materials shows it stood at $2.3 million in 2021, then surged by 30.5% to $3.0 million in 2022, then plummeted by 53.52% to $1.4 million in 2023, then fell by 24.4% to $1.1 million in 2024, then plummeted by 58.28% to $446000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Raw Materials are $446000.0 (Q3 2025), $1.1 million (Q2 2025), and $1.1 million (Q1 2025).